Drugs / Lesinurad
Lesinurad
also known as
Lesinurad component of duzallo · LESINURAD SODIUM · RDEA 594 SODIUM · RDEA594 · Zurampic
Small molecule targets SLC22A12 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Zurampic | — | 2016-02-18 | europa.eu ↗ |
| Approved | US (FDA) | ZURAMPIC | — | 2015-12-22 | fda.gov ↗ |
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT02581553 | Oct 2015 → Jul 2016 | — | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02039700 | Jan → Feb 2014 | — | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01982201 | Nov → Dec 2013 | — | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01986556 | Nov 2013 → Apr 2014 | — | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02028689 | Oct → Nov 2013 | — | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01908257 | Jul → Sep 2013 | — | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01884272 | Jun → Aug 2013 | gout | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01744379 | Dec 2012 → Mar 2013 | gout | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT01001338 | Oct 2009 → Jan 2011 | gout | Ardea Biosciences, Inc. | Completed | Met primary |
| Phase 2 | NCT00955981 | Jul 2009 → Mar 2010 | — | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 37 trials · 3 met primary | ||||||
| Phase 3 | NCT01808144 | Mar 2013 → Aug 2016 | gout | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01808131 | Feb 2013 → Aug 2016 | gout | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01650246 | Aug 2012 → Apr 2014 | gout | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01508702 | Jan 2012 → Oct 2013 | gout | Ardea Biosciences, Inc. | Completed | Met primary |
| Phase 3 | NCT01510769 | Jan 2012 → Jun 2014 | gout | Ardea Biosciences, Inc. | Completed | Mixed |
| Phase 3 | NCT01510158 | Jan 2012 → Jul 2014 | gout | Ardea Biosciences, Inc. | Completed | Met primary |
| Phase 3 | NCT01493531 | Dec 2011 → May 2014 | gout | Ardea Biosciences, Inc. | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03226899 Comparator | Jul 2017 → Feb 2019 | chronic kidney disease, gout | Ironwood Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 12 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lesinurad | “Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.” PMID 26742777 ↗ Jan 2016 |
| Known as | Lesinurad component of duzallo | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105720 ↗ |
| Known as | LESINURAD SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105720 ↗ |
| Known as | RDEA 594 SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105720 ↗ |
| Known as | RDEA594 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00955981 ↗ |
| Known as | Zurampic | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105720 ↗ |
| Action | Inhibit | “oral selective uric acid reabsorption inhibitor” PMID 26742777 ↗ Jan 20161“Solute carrier family 22 member 12 inhibitor” CHEMBL2105720 ↗ |
| Modality | Small molecule | — CHEMBL2105720 ↗ |
| Route | Oral | “lesinurad, an oral selective uric acid reabsorption inhibitor” PMID 26742777 ↗ Jan 2016 |
| Target | SLC22A12 | “Solute carrier family 22 member 12 inhibitor” CHEMBL2105720 ↗ |